Shares of Heron Therapeutics (NASDAQ: HRTX) tumbled from yesterday’s rally after its Q4 Sustol sales results and FY2017 guidance overshadowed separately reported data from phase 2 studies of HTX-011 in patients undergoing bunionectomy (Study 208) and abdominoplasty (Study 203). In a filing, Heron reported Q4 sales of Sustol at $1.1 million and full-year sales of $15 million-$25 million, short of analyst estimates for $2.1 million and $48.8 million, respectively. Regarding the studies: Heron said the results of Study 208 demonstrate statistically significant synergy between the local anesthetic bupivacaine and the anti-inflammatory meloxicam in HTX-011, an extended-release combination product for the prevention of post-operative pain. In Study 203, HTX-011 demonstrated statistically significant reductions in both pain intensity and the use of opioid rescue medications through 96 hours after surgery.
To view the full press releases, visit: http://nnw.fm/z6iRk and http://nnw.fm/7zbjU
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs. Heron is developing novel, patient-focused solutions that apply its innovative science and technologies to already-approved pharmacological agents for patients suffering from cancer or pain. For more information, visit www.herontx.com
About NetworkNewsBreak
NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
